Previous 10 | Next 10 |
CureVac (NASDAQ: CVAC) is working on mRNA coronavirus vaccine candidates. If it's successful, mRNA vaccine giants Moderna and Pfizer will face competition. In this Motley Fool Live video recorded on June 22 , healthcare and cannabis bureau editor and analyst Olivia Z...
CureVac (NASDAQ: CVAC) recently reported disappointing efficacy data from the phase 3 trial of its coronavirus vaccine candidate. The company expects more data and then will decide on what to do next. In this Motley Fool Live video recorded on June 22 , healthcare and cannab...
Many investors thought CureVac (NASDAQ: CVAC) would be the next to market with an mRNA vaccine. And soon. But the vaccine candidate's future looks uncertain after a recent trial report. In this Motley Fool Live video recorded on June 22 , healthcare and cannabis bureau edito...
naphtalina/iStock via Getty Images A few collaboration deals in the drug-development space are sparking big gains in Thursday's pre-market action. Spero Therapeutics (SPRO) posted a notable advance, thanks to an investment from drug-making giant Pfizer (PFE). Orchard Therapeutics (ORTX) climb...
Borqs Technologies (BRQS) -17%.Verb Technology (VERB) -15%.CureVac (CVAC) -13% on final data from phase 2b/3 trial on COVID vaccine.1stdibs.Com (DIBS) -12%.Newegg Commerce (NEGG) -11%.Weidai (WEI) -11%.NovoCure (NVCR) -10% after final results from mid-stage TTFields liver ...
Christian Kaspar-Bartke/Getty Images News Although its COVID-19 vaccine was found to be only 48% effective against any severity of the disease, Curevac (CVAC) says it will move forward with development of the shot, according to CFO Pierre Kemula. Appearing on CNBC this morning, Kemula said th...
Christian Kaspar-Bartke/Getty Images News Shares of CureVac (CVAC) have dropped 8.8% in after-hours trading after the company reported COVID-19 vaccine efficacy of 48% against disease of any severity. The vaccine, CVnCoV, was found to be 77% effective against moderate-to-severe dise...
- Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent - Statistical success criteria for primary endpoint met on basis of 228 adjudicated cases - Vacci...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re taking a look at the biggest pre-market stock movers for Wednesday and that includes the winners and losers. Source: Shutterstock There’s lots to look over this morning as several s...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 30, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Dr. Malte Gr...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...